Company Profile

TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.

Employees

Sector

Biotechnology & Medical Research

More about the company

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	+67.53%

01/10/18	TxCell : Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares	PR
23/07/18	TxCell : Sangamo Therapeutics to Acquire TxCell	PR
10/07/18	TxCell : exercises in-license option to the University of British Columbia’s intellectual property rights of the HLA-A2 CAR-Treg program	PU
21/06/18	TxCell : First in vivo proof-of-concept data with CD8+ CAR-Treg presented at FOCIS 2018	PU
28/05/18	TxCell : to present its latest manufacturing process achievements at the 3rd Annual Bioprocessing of Advanced Cellular Therapies Congress	PU

03/12/18	TxCell : acquisition par Sangamo finalisée
27/11/18	TxCell : retrait obligatoire ce jeudi
26/11/18	TxCell : près de sept millions d'actions apportées à l'OPAS
23/11/18	TXCell : Sangamo Therapeutics dépasse les 90%
15/11/18	TxCell : 'la rencontre avec Sangamo était une évidence'

Manager	Title	Age	Since
Sandrine Boulet COO	Chief Operating Officer	50	-
Pierre Desreumaux PRN	Corporate Officer/Principal	-	-
Bernard Malissen PRN	Corporate Officer/Principal	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TXCELL	-.--%	-.--%	-	-	0
WUXI APPTEC CO., LTD.	+10.00%	+13.39%	+51.99%	+83.45%	56.7B
ARGENX SE	+0.80%	-5.70%	+23.89%	+62.65%	51.97B
BIONTECH SE	+0.92%	+0.88%	-15.24%	-12.42%	23.33B
INSMED INCORPORATED	+0.25%	-4.66%	-10.76%	+351.46%	21.34B
GENMAB A/S	+1.73%	-1.57%	+32.81%	-25.80%	17.44B
PHARMAESSENTIA CORPORATION	+4.29%	+1.67%	+201.24%	+344.48%	14.77B
EXELIXIS, INC.	+1.83%	-0.80%	+52.30%	+176.57%	13.84B
ARROWHEAD PHARMACEUTICALS, INC.	+2.63%	+2.98%	+436.53%	+179.12%	12.12B
MADRIGAL PHARMACEUTICALS, INC.	+5.04%	-6.29%	+61.77%	+159.61%	11.14B
Average	+2.75%	-0.63%	+92.73%	+146.57%	24.74B
Weighted average by Cap.	+3.79%	+0.44%	+62.21%	+117.80%

TxCell Stock

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Press Releases: TxCell

News in other languages: TxCell

Managers and Directors: TxCell

Bio Therapeutic Drugs

Company Profile